EMEA Projects Drug Applications Will Double In 2006
This article was originally published in The Pink Sheet Daily
Agency is unclear why applications are up, but notes that, unlike last year, there have been generic and biosimiliar applications.
You may also be interested in...
GSK is seeking approval to market lapatinib for the treatment of advanced breast cancer in Herceptin-refractory patients.
The Bristol/Gilead combination product will launch within seven business days.
Revatio has the same active ingredient as Viagra, which the company markets for erectile dysfunction, but differs in dosing, pill color and pill shape. Pfizer will launch sildenafil for PAH in mid-July.